KRTX Karuna Therapeutics Inc

Price (delayed)

$124.96

Market cap

$3.37B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.59

Enterprise value

$3.32B

Sector: Healthcare
Industry: Biotechnology

Highlights

KRTX's EPS is up by 30% year-on-year
The debt has declined by 7% since the previous quarter
The company's quick ratio has shrunk by 64% YoY and by 30% QoQ
The net income has plunged by 56% YoY and by 31% from the previous quarter

Key stats

What are the main financial stats of KRTX
Market
Shares outstanding
26.99M
Market cap
$3.37B
Enterprise value
$3.32B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.88
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$68.51M
EBITDA
-$68.37M
Free cash flow
-$70.28M
Per share
EPS
-$2.59
Free cash flow per share
-$2.66
Book value per share
$12.64
Revenue per share
$0
TBVPS
$13.14
Balance sheet
Total assets
$347.63M
Total liabilities
$8.69M
Debt
$2.69M
Equity
$338.93M
Working capital
$337.75M
Liquidity
Debt to equity
0.01
Current ratio
50.28
Quick ratio
47.06
Net debt/EBITDA
0.74
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-18.5%
Return on equity
-18.9%
Return on invested capital
-26.1%
Return on capital employed
-20.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRTX stock price

How has the Karuna Therapeutics stock price performed over time
Intraday
3.44%
1 week
0.15%
1 month
25.69%
1 year
45.81%
YTD
23%
QTD
23%

Financial performance

How have Karuna Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.82M
Net income
-$68.55M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 58% year-on-year and by 28% since the previous quarter
The net income has plunged by 56% YoY and by 31% from the previous quarter

Growth

What is Karuna Therapeutics's growth rate over time

Valuation

What is Karuna Therapeutics stock price valuation
P/E
N/A
P/B
9.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KRTX's EPS is up by 30% year-on-year
The price to book (P/B) is 50% more than the last 4 quarters average of 6.6
The equity has declined by 13% year-on-year and by 5% since the previous quarter

Efficiency

How efficient is Karuna Therapeutics business performance
Karuna Therapeutics's return on equity has increased by 50% YoY but it has decreased by 36% QoQ
Karuna Therapeutics's ROIC has increased by 47% YoY but it has decreased by 17% from the previous quarter
The return on assets has declined by 35% since the previous quarter but it is up by 24% year-on-year

Dividends

What is KRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRTX.

Financial health

How did Karuna Therapeutics financials performed over time
KRTX's total liabilities has soared by 180% YoY and by 21% from the previous quarter
The company's quick ratio has shrunk by 64% YoY and by 30% QoQ
The debt is 99% smaller than the equity
The equity has declined by 13% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.